About Neumora Therapeutics, Inc. - Common Stock (NMRA)
Neumora Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases and psychiatric disorders. The company utilizes a precision medicine approach to target underlying biological mechanisms and aims to create treatments that significantly improve the lives of patients suffering from these conditions. By leveraging advanced drug discovery and development techniques, Neumora is dedicated to addressing unmet medical needs in the field of neuroscience, with a mission to enhance therapeutic outcomes and promote better mental health. Read More
Neumora Therapeutics (NASDAQ: NMRA) shareholders watched their investment collapse today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate workforce reduction of approximately 35%. Investors who lost money on NMRA are encouraged to submit their information now to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 1:35 p.m. ET.
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET.
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws.
LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws.
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY.
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in two investor conferences in November.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology
